Andy
Senior Member (Voting rights)
Merged thread, link and abstract added to post
https://academic.oup.com/jes/article/7/Supplement_1/bvad114.1370/7290078
THU581 Possible Markers For Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Developed In Long Covid: Utility Of Serum Ferritin And Insulin-like Growth Factor-I
Yukichika Yamamoto et al.
Journal of the Endocrine Society, Volume 7, Issue Supplement_1, October-November 2023, bvad114.1370, https://doi.org/10.1210/jendso/bvad114.1370
Published:
05 October 2023
Abstract
Disclosure: Y. Yamamoto: None. Y. Otsuka: None. K. Tokumasu: None. N. Sunada: None. Y. Nakano: None. H. Honda: None. Y. Sakurada: None. T. Hasegawa: None. H. Hagiya: None. F. Otsuka: None.
Almost three years have passed since coronavirus disease 2019 (COVID-19) pandemic broke out, and along with the number of acute COVID-19 patients, the number of patients suffering from chronic prolonged symptoms after COVID-19, long COVID, or post COVID-19 condition, has also increased.
We establised an outpatient clinic specialized for COVID-19 after care (CAC) in Okayama University Hospital in Japan in February 2021.
Our recent study has revealed that the most common symptom is “fatigue”, a part of which potentially may develop into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
However, the pathogenesis and specific prognosticator have yet to be elucidated. The aim of this study was to elucidate the clinical characteristics of patients who developed ME/CFS after COVID-19.
This retrospective observational study investigated the patients who visited our CAC outpatient clinic between February 2021 and March 2022.
Of the 234 patients, 139 (59.4%) had fatigue symptoms, of whom 50 (21.4%) met the criteria for ME/CFS (ME/CFS group), while other 89 did not (non-ME/CFS group); 95 patients had no fatigue complaints (no-fatigue group).
Although the patients’ backgrounds were not significantly different among the three groups, the ME/CFS group presented the highest scores on the self-rating symptom scales, including the Fatigue Assessment Scale (FAS), EuroQol, and Self-Rating Depression Scale (SDS).
Of note, serum ferritin levels, which were correlated to FAS and SDS scores, were significantly higher in the ME/CFS group (193.0 μg/mL; interquartile range (IQR), 58.8-353.8) than those of non-ME/CFS (98.2 μg/mL; 40.4-251.5) and no-fatigue (86.7 μg/mL; 37.5-209.0) groups, and this trend was prominent in the female patients.
Endocrine workup further showed that the ME/CFS group had higher thyrotropin levels but lower growth hormone levels in the serum, and that insulin-like growth factor (IGF)-I levels were inversely correlated with ferritin levels (R = -0.328, p < 0.05).
Collectively, we revealed that serum ferritin levels could be a possible predictor for developing ME/CFS related to long COVID, especially in female patients.
Earlier studies have suggested that hyperferritinemia is a clinical feature in the patients of long COVID, in which hepcidin-like effects could also be involved.
Our present study also uncovered a relationship between hyperferrinemia and endocrine disorders among patients developing ME/CFS after COVID-19, although further investigations are necessary to understand the characteristics of ferritin metabolism.
************
Editorial: Ferritin and myalgic encephalomyelitis/chronic fatigue syndrome in post COVID-19, an unexpected facet of the hyperferritinemic syndrome?
Coronavirus disease 2019 (COVID-19) has provoked a catastrophic medical emergency worldwide [1]. In the course of time from the beginning of this pandemic, subacute and long-term effects in patients suffering from COVID-19 have been increasingly recognised [1,2]. Thus, the term “long-COVID-19” has been proposed to describe this collection of signs and symptoms which may continue or sometimes develop following the SARS-CoV-2 infection. The latter is defined as post-COVID-19 syndrome [3]. In a large percentage of these patients, mental health problems and fibromyalgia have been also recognised [[3], [4], [5]]. Interestingly, many patients could experience severe fatigue in a clinical setting of myalgic encephalitis/chronic fatigue syndrome (ME/CFS), even several months after SARS-CoV-2 infection [6]. In this context, low level inflammation and hypoperfusion have been recently proposed as potential pathomechanisms of occurrence of ME/CFS [7].
On these bases, possible predictors of ME/CFS have been recently investigated in 234 patients with post-COVID-19 syndrome [8]. To date, almost 60% of evaluated patients had fatigue symptoms, and 21.4% met classification criteria for ME/CFS. The authors performed a deep assessment of laboratory features of included patients, stratifying the results in 3 groups, namely patients meeting classification criteria for ME/CFS, patients with fatigue but not reaching the classification criteria for ME/CFS, and patients without fatigue.
Open access, https://www.sciencedirect.com/science/article/pii/S0022399923000880
https://academic.oup.com/jes/article/7/Supplement_1/bvad114.1370/7290078
THU581 Possible Markers For Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Developed In Long Covid: Utility Of Serum Ferritin And Insulin-like Growth Factor-I
Yukichika Yamamoto et al.
Journal of the Endocrine Society, Volume 7, Issue Supplement_1, October-November 2023, bvad114.1370, https://doi.org/10.1210/jendso/bvad114.1370
Published:
05 October 2023
Abstract
Disclosure: Y. Yamamoto: None. Y. Otsuka: None. K. Tokumasu: None. N. Sunada: None. Y. Nakano: None. H. Honda: None. Y. Sakurada: None. T. Hasegawa: None. H. Hagiya: None. F. Otsuka: None.
Almost three years have passed since coronavirus disease 2019 (COVID-19) pandemic broke out, and along with the number of acute COVID-19 patients, the number of patients suffering from chronic prolonged symptoms after COVID-19, long COVID, or post COVID-19 condition, has also increased.
We establised an outpatient clinic specialized for COVID-19 after care (CAC) in Okayama University Hospital in Japan in February 2021.
Our recent study has revealed that the most common symptom is “fatigue”, a part of which potentially may develop into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
However, the pathogenesis and specific prognosticator have yet to be elucidated. The aim of this study was to elucidate the clinical characteristics of patients who developed ME/CFS after COVID-19.
This retrospective observational study investigated the patients who visited our CAC outpatient clinic between February 2021 and March 2022.
Of the 234 patients, 139 (59.4%) had fatigue symptoms, of whom 50 (21.4%) met the criteria for ME/CFS (ME/CFS group), while other 89 did not (non-ME/CFS group); 95 patients had no fatigue complaints (no-fatigue group).
Although the patients’ backgrounds were not significantly different among the three groups, the ME/CFS group presented the highest scores on the self-rating symptom scales, including the Fatigue Assessment Scale (FAS), EuroQol, and Self-Rating Depression Scale (SDS).
Of note, serum ferritin levels, which were correlated to FAS and SDS scores, were significantly higher in the ME/CFS group (193.0 μg/mL; interquartile range (IQR), 58.8-353.8) than those of non-ME/CFS (98.2 μg/mL; 40.4-251.5) and no-fatigue (86.7 μg/mL; 37.5-209.0) groups, and this trend was prominent in the female patients.
Endocrine workup further showed that the ME/CFS group had higher thyrotropin levels but lower growth hormone levels in the serum, and that insulin-like growth factor (IGF)-I levels were inversely correlated with ferritin levels (R = -0.328, p < 0.05).
Collectively, we revealed that serum ferritin levels could be a possible predictor for developing ME/CFS related to long COVID, especially in female patients.
Earlier studies have suggested that hyperferritinemia is a clinical feature in the patients of long COVID, in which hepcidin-like effects could also be involved.
Our present study also uncovered a relationship between hyperferrinemia and endocrine disorders among patients developing ME/CFS after COVID-19, although further investigations are necessary to understand the characteristics of ferritin metabolism.
************
Editorial: Ferritin and myalgic encephalomyelitis/chronic fatigue syndrome in post COVID-19, an unexpected facet of the hyperferritinemic syndrome?
Coronavirus disease 2019 (COVID-19) has provoked a catastrophic medical emergency worldwide [1]. In the course of time from the beginning of this pandemic, subacute and long-term effects in patients suffering from COVID-19 have been increasingly recognised [1,2]. Thus, the term “long-COVID-19” has been proposed to describe this collection of signs and symptoms which may continue or sometimes develop following the SARS-CoV-2 infection. The latter is defined as post-COVID-19 syndrome [3]. In a large percentage of these patients, mental health problems and fibromyalgia have been also recognised [[3], [4], [5]]. Interestingly, many patients could experience severe fatigue in a clinical setting of myalgic encephalitis/chronic fatigue syndrome (ME/CFS), even several months after SARS-CoV-2 infection [6]. In this context, low level inflammation and hypoperfusion have been recently proposed as potential pathomechanisms of occurrence of ME/CFS [7].
On these bases, possible predictors of ME/CFS have been recently investigated in 234 patients with post-COVID-19 syndrome [8]. To date, almost 60% of evaluated patients had fatigue symptoms, and 21.4% met classification criteria for ME/CFS. The authors performed a deep assessment of laboratory features of included patients, stratifying the results in 3 groups, namely patients meeting classification criteria for ME/CFS, patients with fatigue but not reaching the classification criteria for ME/CFS, and patients without fatigue.
Open access, https://www.sciencedirect.com/science/article/pii/S0022399923000880
Last edited by a moderator: